DST and tuberculosis: The most significant finding reported here is that the addition of the KasA inhibitor JSF-3285 increases the bactericidal activity of the BPa and BPaL regimen backbones and shortens the treatment duration needed to prevent relapse in a well-established mouse model of TB.